Search results
Sep 30, 2013 · The aim is come up with a single name – an INN – that can be recognized and used globally by doctors, pharmacists, scientists, medicines regulators and patients. The task is not a simple one, explains Dr Raffaella Balocco Mattavelli, who manages the INN programme at WHO. “Each INN must be unique, distinctive in sound and spelling,” she ...
EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–117) and Recommended (1–78 ...
Proposed INN: List 120 WHO Drug Information, Vol. 32, No. 4, 2018 560 Proposed International Nonproprietary Names: List 120 Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in WHO
When an INN is given for a substance that is a base, the INNM of a salt is created by adding, as a second word, an appropriate designation of the acidic part of the molecule. For this part of the INNM, usual names of acids are used. Abbreviated designations for complicated anions included in the list indicated in para.
Dec 11, 2023 · INN Bio Review 2022. International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2022. 11 December 2023. | Publication.
3.2 General policies for fusion proteins (5) INNs have been assigned to some fusion proteins. If a stem exists for one or the other part of the fusion protein, this stem should be brought into the name. This allows the constant part of a fusion protein to be recognized in the name.
The School of INN (International Nonproprietary Names) In 1950 WHO established the INN Programme to provide a common language for people all over the world to work together for the safe and effective use of medicines. The main objective of the programme is to. define a single, unique, globally accepted name for each pharmaceutical substance.
